학술논문
Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial
Document Type
Article
Author
Source
In The Lancet Diabetes & Endocrinology November 2019 7(11):834-844
Subject
Language
ISSN
2213-8587